Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | teriflunomide | Multiple Sclerosis (MS) | Pending | |||
| N/A | nivolumab ipilimumab | Melanoma | Pending | |||
| N/A | blinatumomab | Acute lymphoblastic leukemia, pediatrics | Pending | |||
| N/A | imiquimod | Gynecological cancers | Withdrawn | |||
| N/A | pembrolizumab | Melanoma (Skin) | Active | |||
| N/A | nivolumab and ipilimumab | Melanoma (Skin) | Active | |||
| N/A | Enzalutamide | Genito-urinary cancer (prostate cancer) | Active | |||
| N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
| N/A | everolimus | Tuberous Sclerosis Complex (TSC) | Active | |||
| N/A | mepolizumab | Eosinophilic Granulomatosis with Polyangiitis | Active |
Last Updated : July 28, 2024